Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC 007 in Long COVID
NCT05911009Phase 2Completed
- Sponsor
- Berlin Cures
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 5
01
Overview
A Phase 2 trial of rovunaptabin in post-acute sequelae of SARS-CoV-2 infection (PASC), sponsored by Berlin Cures. Started Jun 2023; status: completed.
02
Drugs
rovunaptabin
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT05911009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05911009.